Home › Leiomyosarcoma
Leiomyosarcoma clinical trials recruiting in the U.S.
19 studies for Leiomyosarcoma are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX7 studies
- Boston, MA5 studies
- New York City, NY4 studies
- Santa Monica, CA4 studies
- Chicago, IL4 studies
- Nashville, TN3 studies
- Ann Arbor, MI3 studies
- Rochester, MN3 studies
- Columbus, OH3 studies
- Miami, FL3 studies
- Queens, NY3 studies
- St. Louis, MO3 studies
- Aurora, CO3 studies
By state
- California9 studies
- Colorado3 studies
- Florida4 studies
- Illinois4 studies
- Massachusetts5 studies
- Michigan4 studies
- Minnesota3 studies
- Missouri3 studies
- New York4 studies
- Ohio5 studies
- Tennessee4 studies
- Texas7 studies
- Virginia3 studies
Recently updated studies
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05711615Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2026 · NCT01793168STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT06975293A Study of Ivonescimab in People With Leiomyosarcoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07516925Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT06498648AOH1996 for the Treatment of Refractory Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT05227326XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06571734Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 7, 2026 · NCT04031677Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06528769NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Aug 3, 2026 · NCT06239272A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07633756Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07628634Localized Leiomyosarcoma Biomarker Protocol
RecruitingObservational study
All ages · All sexes · Updated Jul 2, 2026 · NCT04925089Metastatic Leiomyosarcoma Biomarker Protocol
RecruitingObservational study
All ages · All sexes · Updated Jun 24, 2026 · NCT05653388A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT06789172Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Feb 25, 2026 · NCT03016819Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RecruitingPhase 2
Ages 65 to 100 · All sexes · Updated Feb 5, 2026 · NCT07125183Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Jun 13, 2025 · NCT06875700Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 24, 2025 · NCT04535271From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.